

BEST AVAILABLE COPY

National
Library
of MedicineMy NC
[Sign In] [Regis]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search PubMed



for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Abstract



Show

20



Sort by



Send to



About Entrez

Text Version

All: 1

Review: 0



Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Acta Diabetol. 1995 Dec;32(4):251-6.

Related Articles, Links

Apolipoprotein AI-CIII-AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus.**Rigoli L, Raimondo G, Di Benedetto A, Romano G, Porcellini A, Campo S, Corica F, Riccardi G, Squadrito G, Cucinotta D.**

Department of Internal Medicine, University of Messina, Italy.

The aim of this study was to verify whether or not the increased prevalence of coronary heart disease (CHD) commonly observed in patients with type 2 diabetes mellitus is related to a genetic background involving restriction fragment length polymorphisms (RFLPs) of apolipoproteins. On the basis of a case-control design, 62 type 2 diabetic patients with CHD (confirmed by clinical history and electrocardiogram) and 62 age- and sex-matched diabetic subjects without CHD were enrolled. In each of them RFLPs of the apolipoprotein CIII gene (S1 or S2 allele) and AI promoter region (A or G allele), together with fasting plasma lipids and apolipoproteins levels, were assessed. The rare S2 allele was found significantly ($P = 0.05$) more frequently in patients with CHD, and its related S1S2 genotype was associated with higher plasma levels of total cholesterol ($P = 0.01$), triglycerides ($P = 0.007$) and apo B ($P = 0.001$) than the S1S1 genotype. The A allele was more frequent ($P = 0.004$) in patients without CHD and was associated with lower plasma cholesterol ($P = 0.0001$), low-density lipoprotein (LDL)-cholesterol ($P = 0.0001$) and apo B ($P = 0.005$). The S1/A haplotype was more frequent ($P = 0.05$) in patients without CHD and was associated with the lowest plasma lipid levels. These results suggest that genetic factors, related to the apo AI-CIII-AIV gene cluster, could play a role in the development of CHD in type 2 diabetic patients, probably through modification of their plasma lipid pattern.

PMID: 8750764 [PubMed - indexed for MEDLINE]

Display

Abstract



Show

20



Sort by



Send to



2132.106

Examiner
copy
reference 3

BEST AVAILABLE COPY

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Apr 18 2005 07:10:12